Drug Type Peptide Conjugate Radionuclide, Diagnostic radiopharmaceuticals, Fluorophore-conjugated therapeutics |
Synonyms (64Cu)-labeled PSMA-targeting -PEG Cy5.5-C' dots, 64Cu-NOTA-PSMA-PEG-Cy5.5-C' dots, PSMA-C' dots |
Target |
Mechanism PSMA inhibitors(Prostate-specific membrane antigen inhibitors), PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Elucida Oncology, Inc.Startup |
Active Organization Elucida Oncology, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Prostatic Cancer | Phase 1 | US | Elucida Oncology, Inc.Startup | 17 Feb 2021 |